乳腺癌中的雌激素相关受体α:从分子洞察到向治疗
Jagannath Pradhan1, Archana Priyadarshini Samal1, Uzma Khatoon1
1School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed to be University, Bhubaneswar, Odisha 751024, India.
Biochimica et biophysica acta. Reviews on cancer
|December 31, 2025
概括
与雌激素相关的受体α (ERRα) 驱动了侵袭性乳腺癌的进展,转移和治疗耐药性. 抑制ERRα显示出治疗具有挑战性的乳腺癌亚型的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 激进的乳腺癌亚型,如HER2阳性和三阴性癌症,预后不好,复发频繁,挑战目前的治疗方法.
- 与雌激素相关的受体α (ERRα),一个孤儿核受体,越来越多地被认为对调节瘤代谢和推动癌症进展的作用.
- 过度表达ERRα与恶性瘤的关键指标相关,包括上皮细胞-介质细胞过渡,血管生成,入侵,转移和治疗抵抗.
研究的目的:
- 审查雌激素相关受体α (ERRα) 在各种乳腺癌亚型的进展中的多方面的作用.
- 突出ERRα作为治疗目标的潜力,以改善侵袭性乳腺癌的治疗结果.
- 巩固目前对ERRα参与瘤代谢,转移和治疗耐药性的理解.
主要方法:
- 关于乳腺癌中雌激素相关受体α (ERRα) 的临床前研究和现有研究的文献综述.
- 分析ERRα表达与侵袭性乳腺癌表型之间的相关性,包括转移和治疗耐药性.
- 检查ERRα抑制 (药理或遗传) 对瘤信号和治疗敏感性的影响.
主要成果:
- 与雌激素相关的受体α (ERRα) 的过度表达在侵袭性乳腺癌亚型中普遍存在,并与预后不佳有关.
- ERRα通过调节能量代谢,上皮细胞-介质细胞过渡,血管生成,侵袭和转移来积极促进瘤的进展.
- 临床前证据表明,向ERRα可以抑制瘤生长并提高对现有疗法的敏感性.
结论:
- 雌激素相关受体α (ERRα) 是侵袭性乳腺癌表型和治疗耐药性的关键驱动因素.
- 向ERRα是一个有希望的治疗策略,用于改善具有挑战性的乳腺癌亚型的治疗结果.
- 对ERRα的机制和临床转化进行进一步的研究是必要的,以便开发新的乳腺癌疗法.
相关概念视频
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:31Transducer Mechanism: Nuclear Receptors
2.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K